Literature DB >> 6121548

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

J M Kane, J M Smith.   

Abstract

Fifty-six prevalence surveys of tardive dyskinesia (TD) in neuroleptic-treated patients are reviewed, yielding an average prevalence of 20% as compared with 5% prevalence of "spontaneous" dyskinesia in 19 samples of untreated individuals. Reported prevalence has increased during the past two decades and is not attributable simply to the more widespread use of rating scales. Controlled studies of a variety of risk factors are reviewed and suggest that advancing age and, to a lesser extent, female sex are the two variables most consistently associated with increased prevalence. There are relatively few data supporting the assumption that the risk of TD development continues to increase with increasing neuroleptic exposure, CNS dysfunction, or exposure to antiparkinsonism medication.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121548     DOI: 10.1001/archpsyc.1982.04290040069010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  88 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Tardive Dyskinesia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Tardive dyskinesia: facts the mental health administrator may not know.

Authors:  K M Slaw; J E Kalachnik
Journal:  J Ment Health Adm       Date:  1985

4.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

5.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

6.  Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats chronically treated with haloperidol.

Authors:  Y Hatta; S Hatta; T Saito
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Tardive dyskinesia associated with metoclopramide.

Authors:  B E Wiholm; O Mortimer; G Boethius; J E Häggström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

8.  Treatment schedule as a determinant of the development of tolerance to haloperidol.

Authors:  R J Carey; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

10.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.